Literature DB >> 34591203

Opposite response of lung adenocarcinoma and its choroidal metastases upon ramucirumab plus docetaxel therapy after immunotherapy: a case report.

Kinnosuke Matsumoto1, Takayuki Shiroyama2, Noriyasu Hashida3, Kotaro Miyake1, Yuji Yamamoto1, Tomoki Kuge1, Midori Yoneda1, Makoto Yamamoto1, Yujiro Naito1, Yasuhiko Suga1, Kiyoharu Fukushima1, Shohei Koyama1, Kota Iwahori1, Haruhiko Hirata1, Izumi Nagatomo1, Yoshito Takeda1, Atsushi Kumanogoh1.   

Abstract

We report a unique case of advanced non-small cell lung cancer that exhibited the opposite response to its unilateral choroidal metastases upon ramucirumab plus docetaxel treatment. A combination of cisplatin, pemetrexed, and pembrolizumab was administered as first-line treatment, resulting in shrinkage of all the lesions. However, although the patient was continued on a course of pembrolizumab, all the lesions had recurred approximately two months later. Ramucirumab plus docetaxel, administered as sequential treatment, resulted in maintained shrinkage of the choroidal lesions, yet all the other lesions progressed. Ramucirumab may be a suitable therapy for choroidal metastases, especially if administered immediately after immunotherapy.
© 2021. The Author(s), under exclusive licence to Springer Nature B.V.

Entities:  

Keywords:  Case report; Choroidal metastasis; Docetaxel; Lung adenocarcinoma; Ramucirumab

Mesh:

Substances:

Year:  2021        PMID: 34591203     DOI: 10.1007/s10456-021-09820-7

Source DB:  PubMed          Journal:  Angiogenesis        ISSN: 0969-6970            Impact factor:   9.596


  7 in total

Review 1.  Anti-angiogenic agents - overcoming tumour endothelial cell anergy and improving immunotherapy outcomes.

Authors:  Zowi R Huinen; Elisabeth J M Huijbers; Judy R van Beijnum; Patrycja Nowak-Sliwinska; Arjan W Griffioen
Journal:  Nat Rev Clin Oncol       Date:  2021-04-08       Impact factor: 66.675

2.  Addition of ramucirumab enhances docetaxel efficacy in patients who had received anti-PD-1/PD-L1 treatment.

Authors:  Takehiro Tozuka; Satoru Kitazono; Hiroaki Sakamoto; Hiroshi Yoshida; Yoshiaki Amino; Shinya Uematsu; Takahiro Yoshizawa; Tsukasa Hasegawa; Ryo Ariyasu; Ken Uchibori; Noriko Yanagitani; Takeshi Horai; Masahiro Seike; Akihiko Gemma; Makoto Nishio
Journal:  Lung Cancer       Date:  2020-04-25       Impact factor: 5.705

3.  Survey of 520 eyes with uveal metastases.

Authors:  C L Shields; J A Shields; N E Gross; G P Schwartz; S E Lally
Journal:  Ophthalmology       Date:  1997-08       Impact factor: 12.079

4.  Intravitreal bevacizumab (Avastin) for choroidal metastasis secondary to breast carcinoma: short-term follow-up.

Authors:  L Amselem; E Cervera; M Díaz-Llopis; J Montero; M Garcia-Pous; P Udaondo; S García-Delpech; D Salom
Journal:  Eye (Lond)       Date:  2006-11-24       Impact factor: 3.775

5.  Vaccination of pregnant rhesus monkeys with inactivated rotavirus as a model for achieving protection from rotavirus SA11 infection in the offspring.

Authors:  Na Yin; Jinyuan Wu; Xiangjing Kuang; Xiaochen Lin; Yan Zhou; Shan Yi; Xiaoqing Hu; Rong Chen; Yaling Liu; Jun Ye; Zhanlong He; Maosheng Sun; Hongjun Li
Journal:  Hum Vaccin Immunother       Date:  2021-12-02       Impact factor: 3.452

6.  Efficacy of Docetaxel Plus Ramucirumab as Palliative Third-Line Therapy Following Second-Line Immune-Checkpoint-Inhibitor Treatment in Patients With Non-Small-Cell Lung Cancer Stage IV.

Authors:  Wolfgang M Brueckl; Martin Reck; Achim Rittmeyer; Jens Kollmeier; Claas Wesseler; Gunther H Wiest; Petros Christopoulos; Amanda Tufman; Petra Hoffknecht; Bernhard Ulm; Fabian Reich; Joachim H Ficker; Eckart Laack
Journal:  Clin Med Insights Oncol       Date:  2020-08-19

Review 7.  New concepts in the diagnosis and management of choroidal metastases.

Authors:  Thibaud Mathis; Pauline Jardel; Olivier Loria; Benoit Delaunay; Anh-Minh Nguyen; Francesco Lanza; Carlo Mosci; Jean-Pierre Caujolle; Laurent Kodjikian; Juliette Thariat
Journal:  Prog Retin Eye Res       Date:  2018-09-19       Impact factor: 21.198

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.